429 Long-term analysis of MASTERKEY-265 phase 1b trial of talimogene laherparepvec (T-VEC) plus pembrolizumab in patients with unresectable stage IIIB-IVM1c melanoma

• Antoni Ribas,
• Olivier Michielin,
• Reinhard Dummer,
• Scott Diede,
• Salvador Martin-Algarra,
• Sheryl Treichel,
• Edward Chan

Affiliations

Antoni Ribas

Aff1 grid.19006.3e0000000096326718Department of Medicine (Division of Hematology-Oncology) at David Geffen School of MedicineUniversity of California Los Angeles (UCLA) Los Angeles USA

Olivier Michielin

Aff1 grid.8515.90000000104234662Department of OncologyCHUV Service of Oncology and Ludwig Cancer Research Center Lausanne Switzerland

Reinhard Dummer

Department of Dermatology, University Hospital and University of Zurich, Zurich, Switzerland

Scott Diede

12Merck and Co., Inc., Kenilworth, NJ, USA

Salvador Martin-Algarra

5Clínica Universidad de Navarra (CUN), Medical School of the University of Navarra, Pamplona, Spain

Sheryl Treichel

6Amgen Inc., Thousand Oaks, CA, USA

Edward Chan

6Amgen Inc., Thousand Oaks, CA, USA